Estudo de fase 2, braço único | Sobrevida geral e análise de biomarcadores do nivolumabe neoadjuvante com quimioterapia no câncer de pulmão de não pequenas células operável estágio IIIA.

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) – Journal of Clinical Oncology

Comentário no Twitter

In NADIM study of neoadj chemo + nivo for stage IIIA NSCLC, 3-y OS was 91%; low levels of pretreatment ctDNA and undetectable ctDNA after neoadjuvant therapy were predictive of OS (with HRs of 0.07 and 0.04, respectively) https://t.co/BIprSnDICd

— NatureRevClinOncol (@NatRevClinOncol) May 18, 2022